Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir

Transplant Infectious Disease

Volumn 12, Issue 6, 2010, Pages 513-517

  Renaud, C ^a,b   Pergam, S A ^b   Polyak, C ^b   Jain, R ^b   Kuypers, J ^c   Englund, J A ^b,d   Corey, L ^b,c   Boeckh, M J ^b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b USA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

H275Y; Influenza; Peramivir; Resistance; Zanamivir

Indexed keywords

IMIPENEM; IMMUNOGLOBULIN; LEVOFLOXACIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSELTAMIVIR; PERAMIVIR; PREDNISONE; RIBAVIRIN; RIMANTADINE; TACROLIMUS; VANCOMYCIN; ZANAMIVIR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE HEMORRHAGIC PANCREATITIS; ADULT; ANTIVIRAL RESISTANCE; AORTA VALVE; ARTICLE; BRONCHOSCOPY; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; DIALYSIS; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ENDOCARDITIS; FEVER; GENE MUTATION; GRAFT RECIPIENT; HALLUCINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; ILEUS; IMMUNOCOMPROMISED PATIENT; INFLUENZA; INFLUENZA VIRUS A H1N1; INTUBATION; KIDNEY FAILURE; LUNG EMBOLISM; LUNG LAVAGE; LYMPHOCYTOPENIA; MALE; NAUSEA; OLIGURIA; PRIORITY JOURNAL; REPEAT PROCEDURE; TACHYPNEA; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; VEIN THROMBOSIS; VIRUS LOAD; VITAL SIGN; VOMITING;

ANTIVIRAL AGENTS; CYCLOPENTANES; DRUG RESISTANCE, VIRAL; FATAL OUTCOME; GUANIDINES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MUTATION; NEURAMINIDASE; OSELTAMIVIR;

EID: 78650078076     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00582.x     Document Type: Article

References (23)

1. Redelman-Sidi G, Sepkowitz KA, Huang CK, et al. 2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients. J Infect 2010; 60 (4): 257-263.
2. Kharfan-Dabaja MA, Velez A, Richards K, Greene JN, Field T, Sandin R. Influenza A/pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population. Int J Hematol 2010; 91 (1): 124-127.
3. Birnkrant D, Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009; 361 (23): 2204-2207.
4. Baz M, Abed Y, Boivin G. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res 2007; 74 (2): 159-162.
5. Liu CM, Driebe EM, Schupp J, et al. Rapid quantification of single-nucleotide mutations in mixed influenza A viral populations using allele-specific mixture analysis. J Virol Methods 2010; 163 (1): 109-115.
6. Renaud C, Kuypers J, Corey L. Diagnostic accuracy of an allele-specific reverse transcriptase-PCR assay targeting the H275Y oseltamivir resistant mutation in 2009 pandemic influenza A/H1N1 virus. J Clin Virol 2010; 49 (1): 21-25.
7. Deyde VM, Gubareva LV. Influenza genome analysis using pyrosequencing method: current applications for a moving target. Expert Rev Mol Diagn 2009; 9 (5): 493-509.
8. Update on oseltamivir-resistant pandemic A (H1N1) 2009 influenza virus: January 2010. Wkly Epidemiol Rec 2009; 85 (6): 37-40.
9. Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother 2010; 54 (9): 3671-3677.
10. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010; 50 (9): 1252-1255.
11. Englund J, Zerr D, Pergam S, et al. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 2009; 58 (32): 893-896.
12. Gaur AH, Bagga B, Barman S, et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 2010; 362 (1): 88-89.
13. Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010; 182 (4): 357-363.
14. Mancuso CE, Gabay MP, Steinke LM, Vanosdol SJ. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza. Ann Pharmacother 2010; 44 (7-8): 1240-1249.
15. Baz M, Abed Y, Simon P, Hamelin ME, Boivin G. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A (H1N1) viruses. J Infect Dis 2010; 201 (5): 740-745.
16. Duan S, Boltz DA, Seiler P, et al. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog 2010; 6 (7): e1001022.
17. Matsuzaki Y, Mizuta K, Aoki Y, et al. A two-year survey of the oseltamivir-resistant influenza A (H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol J 2010; 7: 53.
18. Tamura D, Mitamura K, Yamazaki M, et al. Oseltamivir-resistant influenza A viruses circulating in Japan. J Clin Microbiol 2009; 47 (5): 1424-1427.
19. Ujike M, Shimabukuro K, Mochizuki K, et al. Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan. Emerg Infect Dis 2010; 16 (6): 926-935.
20. Saito R, Sato I, Suzuki Y, et al. Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation. Pediatr Infect Dis J 2010; 29 (10): 898-904.
21. Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis 2008; 21 (6): 626-638.
22. Okomo-Adhiambo M, Nguyen HT, Sleeman K, et al. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A (H1N1) viruses. Antiviral Res 2010; 85 (2): 381-388.
23. Nguyen JT, Hoopes JD, Le MH, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010; 5 (2): e9332.